Avonex’s freefall still likely amid patent case loss

  1. Avonex’s freefall still likely amid patent case loss  BioPharma Dive

  2. Biogen’s Multiple Sclerosis Drug Franchise Takes Another Hit  Investor’s Business Daily

    3. Full coverage